- Home
- ARQT
as 06-20-2025 12:31pm EST
Arcutis Biotherapeutics Inc is a medical dermatology company. It is developing treatments for patients with immune-mediated dermatological diseases and conditions. It is leveraging recent advances in immunology and inflammation to develop differentiated therapies against biologically validated targets to solve persistent treatment challenges in serious diseases of the skin. The company's product candidate ZORYVE roflumilast cream, has completed pivotal Phase 3 clinical trials in plaque psoriasis, demonstrating symptomatic improvement and favorable tolerability in this population.
| Founded: | 2016 | Country: | United States |
| Employees: | N/A | City: | WESTLAKE VILLAGE |
| Market Cap: | 1.7B | IPO Year: | 2020 |
| Target Price: | $18.80 | AVG Volume (30 days): | 2.0M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 6 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.04 | EPS Growth: | N/A |
| 52 Week Low/High: | $7.63 - $17.75 | Next Earning Date: | 08-13-2025 |
| Revenue: | $212,819,000 | Revenue Growth: | 100.03% |
| Revenue Growth (this year): | 61.15% | Revenue Growth (next year): | 37.98% |
Stock Insider Trading Activity of Arcutis Biotherapeutics Inc. (ARQT)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Heron Patrick J | ARQT | Director | Jun 13 '25 | Buy | $13.08 | 2,646 | $34,610.47 | 27,448 | |
| Heron Patrick J | ARQT | Director | Jun 4 '25 | Buy | $13.37 | 2,268 | $30,246.73 | 27,448 | |
| Matsuda Masaru | ARQT | See Remarks | May 28 '25 | Sell | $13.78 | 1,800 | $24,806.52 | 202,599 | |
| Heron Patrick J | ARQT | Director | May 21 '25 | Buy | $13.66 | 5,040 | $68,821.20 | 27,448 | |
| Edwards Larry Todd | ARQT | See Remarks | May 19 '25 | Sell | $14.07 | 7,451 | $104,849.73 | 183,104 | |
| Heron Patrick J | ARQT | Director | May 15 '25 | Buy | $13.62 | 2,520 | $34,316.86 | 27,448 | |
| Heron Patrick J | ARQT | Director | May 13 '25 | Buy | $13.76 | 8,674 | $119,351.93 | 27,448 | |
| Heron Patrick J | ARQT | Director | May 9 '25 | Buy | $13.60 | 6,300 | $85,691.34 | 27,448 | |
| Burnett Patrick | ARQT | See Remarks | May 8 '25 | Sell | $13.59 | 3,871 | $52,623.15 | 115,468 | |
| Matsuda Masaru | ARQT | See Remarks | May 2 '25 | Sell | $15.20 | 5,030 | $76,453.49 | 202,599 |
Latest Arcutis Biotherapeutics Inc. News
ARQT Breaking Stock News: Dive into ARQT Ticker-Specific Updates for Smart Investing
Simply Wall St.
2 days ago
Analysts Expect Breakeven For Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Before Long
Insider Monkey
5 days ago
Arcutis Biotherapeutics (ARQT) Announces Enrolling the First Child in Phase 2 Trials
Clinical Trials Arena
9 days ago
First child enrolled in Arcutis’ Phase II trial of cream for atopic dermatitis
GlobeNewswire
10 days ago
Arcutis Enrolls First Child in INTEGUMENT-INFANT Evaluating ZORYVE® (roflumilast) Cream 0.05% in Infants with Atopic Dermatitis
GlobeNewswire
14 days ago
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire
14 days ago
Arcutis to Present New Long-Term Results of ZORYVE® (roflumilast) Cream at the 2025 Revolutionizing Atopic Dermatitis Conference
GlobeNewswire
22 days ago
Arcutis to Present at the Goldman Sachs 46th Annual Global Healthcare Conference
MT Newswires
a month ago
Arcutis Biotherapeutics' Foam Psoriasis Treatment Gets FDA Approval
Compare ARQT vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "ARQT Arcutis Biotherapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.